InMed Pharmaceuticals Inc (INM)

InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing RequirementsJune 4, 2026 5:00 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - June 4, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), today announce that it had received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 3, 2026 informing the Company that it has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq.As previously disclosed, the Company was notified by Nasdaq on March 27, 2026 that its common shares had failed to maintain a minimum bid price of $1.00 per share for 30 consecutive business days. Nasdaq has now determined that the closing bid price of the Company's common stock was at or above $1.00 per share for 10 consecutive business days from May 19, 2026 to June 2, 2026. Accordingly, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), and Nasdaq has advised the Company that the matter has been closed.About InMed PharmaceuticalsInMed is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com. Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.comCautionary Note Regarding Forward-Looking Information:This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about the Company's ability to maintain compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement for continued listing on Nasdaq, in the future.With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things: the ability to maintain the minimum bid price of the Company's common shares at or above $1.00 per share on a sustained basis; the continued listing of the Company's common shares on Nasdaq; the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing the Company's business is disclosed in its Annual Report on Form 10-K, Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov.All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300271 Original: InMed Pharmaceuticals Regains Compliance with Nasdaq Continued Listing Requirements

/C O R R E C T I O N -- InMed Pharmaceuticals/May 20, 2026 10:34 AM
PR Newswire (US) In the news release, InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies, issued 19-May-2026 by InMed Pharmaceuticals over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapiesConcurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations through 2028First-in-human regulatory filings for MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) expected mid-2026 and 1Q 2027, respectivelyConference call scheduled for May 19, 2026, at 8:30 AM EDTVANCOUVER, BC and SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") is pleased to announce that it has entered into a definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp. a wholly-owned subsidiary of InMed, and Indigo Merger Sub II, LLC, a wholly-owned subsidiary of InMed. The merger brings together Mentari's differentiated migraine pipeline with InMed's public market infrastructure, positioning the combined company to expedite the development of new therapies for people living with migraine, a debilitating neurological disorder affecting more than 1 billion people globally. Upon consummation of the transaction contemplated by the Agreement, the combined entity will operate as Mentari Therapeutics and trade on the Nasdaq Capital Market under a new ticker symbol. The concurrent private placement (the "Private Placement") was led by Fairmount with participation from Commodore Capital, Deep Track Capital, Janus Henderson Investors, a16z Bio + Health, Venrock Healthcare Capital Partners, Wellington Management, TCGX, Blackstone Multi-Asset Investing, BB Biotech, Farallon Capital, RTW Investments, LP, Vivo Capital, Perceptive Advisors, Sirenia Capital Management LP and other leading investment management firms. The Private Placement will result in gross proceeds to the combined company of approximately US$290 million and is expected to fully fund its operations through 2028, beyond the generation of anticipated key clinical datasets from Mentari's parallel lead programs. These programs include MT-001, an anti-PACAP (pituitary adenylate cyclase-activating polypeptide) monoclonal antibody with Phase 2a proof-of-concept data expected in 2028, and MT-002, a potentially first-in-class anti-CGRP (calcitonin gene-related peptide) and anti-PACAP bispecific antibody with Phase 1 healthy volunteer data expected in 2027. Together, MT-001 and MT-002 target validated, complementary, and orthogonal pathways in migraine pathophysiology and have potential to address the significant unmet need in individuals suffering from chronic and episodic migraine. Approximately 40-50% of patients treated with current approved therapies do not achieve a 50% reduction in monthly migraine days (MMDs), and fewer than one-third of patients have a 75% reduction in MMDs."This merger with Mentari represents an excellent opportunity for InMed shareholders to participate in the development of an exciting new drug pipeline with significant therapeutic and commercial potential," said Eric A. Adams, President and CEO of InMed. "InMed's Board of Directors and management team are in full support of this transaction and believe that Mentari's strong balance sheet positions the company to successfully execute on the development plans for its parallel lead programs in the treatment of migraines. We believe Mentari's lead programs have tremendous potential to expand and reshape the migraine treatment and prevention market.""This transaction provides us with the capital and public market infrastructure to aggressively compete in what we believe will be the next era of migraine prevention," said Julie Bruno, Chair of Mentari's board. "Recent anti-PACAP clinical studies have validated this novel mechanism and generated tremendous excitement among headache specialists. MT-001 and MT-002 were designed to be potentially best-in-class, with superior convenience through subcutaneous delivery and the potential for enhanced efficacy through rational dual pathway inhibition. We have a clear regulatory path, rapid development timelines benchmarked to approved migraine therapies, and are focused on bringing these potentially transformative therapies to the millions of people who continue to suffer despite current treatment options."Mentari's pipeline programs were discovered by Paragon Therapeutics, Inc. and the co-lead programs, MT-001 and MT-002, have demonstrated equal or superior in vitro potency compared to benchmark antibodies, with pharmacokinetic profiles in non-human primates projected to enable convenient subcutaneous dosing in humans.Conference Call DetailsInMed will host a conference call on Tuesday, May 19th, at 8:30 am ET to discuss the merger details. To join the call, please dial (888) 880-3330 (U.S Toll Free) or (800) 715-9871 (Canada Toll Free). A replay of the call will be temporarily archived on the Investors section of InMed's website following the presentation.About the Proposed TransactionUnder the terms of the merger agreement, as of the closing of the proposed merger, the pre-merger InMed shareholders are expected to own approximately 1.51% of the combined company, which is expected to have a pro forma equity value of approximately US$421.4 million (inclusive of the Private Placement). The percentage of the combined company that InMed's shareholders will own as of the closing of the proposed merger is subject to adjustment based on the estimated amount of InMed's net cash immediately prior to the closing date.In addition, InMed shareholders as of immediately prior to Closing (the "Holders") will be entitled to receive additional financial consideration through (i) a potential distribution or dividend (if any) (1) payable upon a pre-closing sale, license, divestiture or other monetization transaction (i.e., a royalty transaction) of InMed research and development programs (a "Parent Legacy Transaction"), and (2) to the extent closing net cash exceeds certain thresholds described in the Agreement; and (ii) a contingent value right entitling the Holders to proceeds (if any) from a Parent Legacy Transaction received post-closing, in each case the terms of which will be described in the Agreement and/or Form 8-K to be filed in connection with the proposed transaction.The transaction has received approval by the Board of Directors of both companies and is expected to close in the second half of 2026, subject to certain closing conditions, including, among others, approval by the stockholders of each company, the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission (the "SEC") to register the securities to be issued in connection with the proposed merger and the satisfaction of other customary closing conditions.The combined company plans to operate under the name Mentari Therapeutics, Inc. Mentari's existing Board of Directors will become directors of the combined company, chaired by Julie Bruno, Growth Partner at Fairmount, and including Michelle Pernice, Operating Partner at Fairmount, and Laura Sandler, Chief Operating Officer at Oruka Therapeutics.Lucid Capital Markets, LLC is serving as financial advisor and Norton Rose Fulbright LLP and Norton Rose Fulbright Canada LLP are serving as legal counsel to InMed. Wedbush Securities Inc. is serving as exclusive strategic financial advisor and Gibson, Dunn & Crutcher LLP is serving as legal counsel to Mentari. Jefferies, TD Cowen, Stifel, Guggenheim Securities, and Wedbush & Co., LLC are serving as the placement agents to Mentari. Cooley LLP is serving as legal counsel to the placement agents.About InMed PharmaceuticalsInMed is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.About Mentari TherapeuticsMentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine to deliver freedom from this debilitating and undertreated neurological condition that affects more than 1 billion people globally. Mentari's lead programs target PACAP, a newly validated target that is mechanistically independent from CGRP, one of the first migraine targets to yield clinical and commercial success. Mentari's pipeline includes MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing, and MT-002, an anti-CGRP and anti-PACAP bispecific antibody designed to inhibit these complementary pathways with potential to deliver superior outcomes for people with incomplete response to CGRP-targeted therapies. The company's programs were discovered by Paragon Therapeutics. Mentari is based in Waltham, MA. For more information, visit mentaritx.com.Forward Looking StatementsCertain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to InMed's and Mentari's expectations, hopes, beliefs, intentions or strategies regarding the proposed merger, the Private Placement, and the combined company's future, pipeline and business including, without limitation, statements regarding the expected timing and completion of the proposed merger and the Private Placement, the anticipated ownership structure of the combined company, the expected benefits, opportunities and market potential of the proposed transaction, the combined company's ability to achieve the expected benefits or opportunities with respect to its product candidates, including whether MT-001 and MT-002 will achieve clinical proof of concept, demonstrate superior efficacy or potency, achieve convenient dosing, address unmet need in CGRP inadequate responders, or achieve regulatory approval and statements made herein with respect to (i) a potential distribution or dividend (if any) (A) payable upon a Parent Legacy Transaction, and (B) to the extent closing net cash exceeds certain thresholds described in the Agreement, and (ii) the contingent value rights entitling the Holders to proceeds (if any) from a Parent Legacy Transaction received post-closing. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the combined company will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond InMed's, Mentari's or the combined company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to: the risk that the proposed merger and the Private Placement may not be completed on the anticipated timeline or at all; the failure to satisfy the conditions to closing, including obtaining the requisite approvals of the stockholders of each company and the effectiveness of the registration statement to be filed with the SEC in connection with the proposed merger; the risk that the Private Placement may not close or may not result in the anticipated gross proceeds; the outcome of preclinical studies and clinical trials; regulatory approval processes; the combined company's ability to successfully develop and commercialize its product candidates; competition in the migraine treatment market; the combined company's reliance on third parties; protection of intellectual property; and the combined company's need for substantial additional funding. Should one or more of these risks or uncertainties materialize, or should any of InMed's, Mentari's or the combined company's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and in InMed's filings with the SEC. InMed, Mentari and the combined company do not undertake or accept any duty to make any updates or revisions to any forward-looking statements, except as required by law.Important Information About Investigational Product CandidatesThis press release concerns drug candidates that are under preclinical and clinical investigation, and which have not yet been approved by the U.S. Food and Drug Administration. These are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.No Offer or SolicitationThis press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any proxy, vote, consent or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities to be sold in the Private Placement are being offered in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.Important Additional Information About the Proposed Transaction Will Be Filed with the SECIn connection with the proposed merger, InMed intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a proxy statement/prospectus relating to the proposed transaction. This press release is not a substitute for the registration statement, proxy statement/prospectus or any other document that InMed may file with the SEC in connection with the proposed transaction.INVESTORS AND SECURITY HOLDERS OF INMED AND MENTARI ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT INMED, MENTARI, THE PROPOSED TRANSACTION AND RELATED MATTERS.Investors and security holders will be able to obtain free copies of the registration statement, proxy statement/prospectus and other documents filed by InMed with the SEC through the website maintained by the SEC at www.sec.gov and on the Investors section of InMed's website.Participants in the SolicitationInMed, Mentari and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from InMed's stockholders in connection with the proposed transaction. Information about InMed's directors and executive officers, including a description of their interests in InMed, is contained in InMed's most recent Annual Report on Form 10-K and subsequent reports filed with the SEC. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the proposed transaction, including a description of their direct or indirect interests, by security holdings or otherwise, will be included in the registration statement and proxy statement/prospectus when filed with the SEC.Media ContactLia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.comInvestor Contact
Colin Clancy
Vice President, Investor Relations
and Corporate Communications, InMed Pharmaceuticals Inc.
T:  +1.604.416.0999
E:   ir@inmedpharma.comCorrection: An update has been made to the last sentence of paragraph 11. Additionally, Sirenia Capital Management LP has been added to the list of investment management firms in the second paragraph. View original content to download multimedia:https://www.prnewswire.com/news-releases/inmed-pharmaceuticals--mentari-therapeutics-announce-merger-to-advance-migraine-prevention-therapies-302776112.htmlSOURCE InMed Pharmaceuticals Original: /C O R R E C T I O N -- InMed Pharmaceuticals/

/C O R R E C T I O N -- InMed Pharmaceuticals/May 19, 2026 2:21 PM
PR Newswire (US) In the news release, InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies, issued 19-May-2026 by InMed Pharmaceuticals over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end: InMed Pharmaceuticals & Mentari Therapeutics Announce Merger to Advance Migraine Prevention Therapies Mentari's parallel lead programs target validated, complementary pathways with potential to address the two-thirds of patients who have a suboptimal response to anti-CGRP therapiesConcurrent oversubscribed US$290 million private placement of Mentari expected to fund company operations through 2028First-in-human regulatory filings for MT-001 (anti-PACAP) and MT-002 (anti-CGRP x PACAP bispecific) expected mid-2026 and 1Q 2027, respectivelyConference call scheduled for May 19, 2026, at 8:30 AM EDTVANCOUVER, BC and SAN FRANCISCO, May 19, 2026 /PRNewswire/ -- InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") is pleased to announce that it has entered into a definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp. a wholly-owned subsidiary of InMed, and Indigo Merger Sub II, LLC, a wholly-owned subsidiary of InMed. The merger brings together Mentari's differentiated migraine pipeline with InMed's public market infrastructure, positioning the combined company to expedite the development of new therapies for people living with migraine, a debilitating neurological disorder affecting more than 1 billion people globally. Upon consummation of the transaction contemplated by the Agreement, the combined entity will operate as Mentari Therapeutics and trade on the Nasdaq Capital Market under a new ticker symbol. The concurrent private placement (the "Private Placement") was led by Fairmount with participation from Commodore Capital, Deep Track Capital, Janus Henderson Investors, a16z Bio + Health, Venrock Healthcare Capital Partners, Wellington Management, TCGX, Blackstone Multi-Asset Investing, BB Biotech, Farallon Capital, RTW Investments, LP, Vivo Capital, Perceptive Advisors and other leading investment management firms. The Private Placement will result in gross proceeds to the combined company of approximately US$290 million and is expected to fully fund its operations through 2028, beyond the generation of anticipated key clinical datasets from Mentari's parallel lead programs. These programs include MT-001, an anti-PACAP (pituitary adenylate cyclase-activating polypeptide) monoclonal antibody with Phase 2a proof-of-concept data expected in 2028, and MT-002, a potentially first-in-class anti-CGRP (calcitonin gene-related peptide) and anti-PACAP bispecific antibody with Phase 1 healthy volunteer data expected in 2027. Together, MT-001 and MT-002 target validated, complementary, and orthogonal pathways in migraine pathophysiology and have potential to address the significant unmet need in individuals suffering from chronic and episodic migraine. Approximately 40-50% of patients treated with current approved therapies do not achieve a 50% reduction in monthly migraine days (MMDs), and fewer than one-third of patients have a 75% reduction in MMDs."This merger with Mentari represents an excellent opportunity for InMed shareholders to participate in the development of an exciting new drug pipeline with significant therapeutic and commercial potential," said Eric A. Adams, President and CEO of InMed. "InMed's Board of Directors and management team are in full support of this transaction and believe that Mentari's strong balance sheet positions the company to successfully execute on the development plans for its parallel lead programs in the treatment of migraines. We believe Mentari's lead programs have tremendous potential to expand and reshape the migraine treatment and prevention market.""This transaction provides us with the capital and public market infrastructure to aggressively compete in what we believe will be the next era of migraine prevention," said Julie Bruno, Chair of Mentari's board. "Recent anti-PACAP clinical studies have validated this novel mechanism and generated tremendous excitement among headache specialists. MT-001 and MT-002 were designed to be potentially best-in-class, with superior convenience through subcutaneous delivery and the potential for enhanced efficacy through rational dual pathway inhibition. We have a clear regulatory path, rapid development timelines benchmarked to approved migraine therapies, and are focused on bringing these potentially transformative therapies to the millions of people who continue to suffer despite current treatment options."Mentari's pipeline programs were discovered by Paragon Therapeutics, Inc. and the co-lead programs, MT-001 and MT-002, have demonstrated equal or superior in vitro potency compared to benchmark antibodies, with pharmacokinetic profiles in non-human primates projected to enable convenient subcutaneous dosing in humans.Conference Call DetailsInMed will host a conference call on Tuesday, May 19th, at 8:30 am ET to discuss the merger details. To join the call, please dial (888) 880-3330 (U.S Toll Free) or (800) 715-9871 (Canada Toll Free). A replay of the call will be temporarily archived on the Investors section of InMed's website following the presentation.About the Proposed TransactionUnder the terms of the merger agreement, as of the closing of the proposed merger, the pre-merger InMed shareholders are expected to own approximately 1.51% of the combined company, which is expected to have a pro forma equity value of approximately US$421.4 million (inclusive of the Private Placement). The percentage of the combined company that InMed's shareholders will own as of the closing of the proposed merger is subject to adjustment based on the estimated amount of InMed's net cash immediately prior to the closing date.In addition, InMed shareholders as of immediately prior to Closing (the "Holders") will be entitled to receive additional financial consideration through (i) a potential distribution or dividend (if any) (1) payable upon a pre-closing sale, license, divestiture or other monetization transaction (i.e., a royalty transaction) of InMed research and development programs (a "Parent Legacy Transaction"), and (2) to the extent closing net cash exceeds certain thresholds described in the Agreement; and (ii) a contingent value right entitling the Holders to proceeds (if any) from a Parent Legacy Transaction received post-closing, in each case the terms of which will be described in the Agreement and/or Form 8-K to be filed in connection with the proposed transaction.The transaction has received approval by the Board of Directors of both companies and is expected to close in the second half of 2026, subject to certain closing conditions, including, among others, approval by the stockholders of each company, the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission (the "SEC") to register the securities to be issued in connection with the proposed merger and the satisfaction of other customary closing conditions.The combined company plans to operate under the name Mentari Therapeutics, Inc. Mentari's existing Board of Directors will become directors of the combined company, chaired by Julie Bruno, Growth Partner at Fairmount, and including Michelle Pernice, Operating Partner at Fairmount, and Laura Sandler, Chief Operating Officer at Oruka Therapeutics.Lucid Capital Markets, LLC is serving as financial advisor and Norton Rose Fulbright LLP and Norton Rose Fulbright Canada LLP are serving as legal counsel to InMed. Wedbush Securities Inc. is serving as exclusive strategic financial advisor and Gibson, Dunn & Crutcher LLP is serving as legal counsel to Mentari. Jefferies, TD Cowen, Stifel, Guggenheim Securities, and Wedbush & Co., LLC are serving as the placement agents to Mentari. Cooley LLP is serving as legal counsel to the placement agents.About InMed PharmaceuticalsInMed is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.About Mentari TherapeuticsMentari Therapeutics is a biotechnology company developing therapies for the prevention of migraine to deliver freedom from this debilitating and undertreated neurological condition that affects more than 1 billion people globally. Mentari's lead programs target PACAP, a newly validated target that is mechanistically independent from CGRP, one of the first migraine targets to yield clinical and commercial success. Mentari's pipeline includes MT-001, an anti-PACAP monoclonal antibody designed for convenient subcutaneous dosing, and MT-002, an anti-CGRP and anti-PACAP bispecific antibody designed to inhibit these complementary pathways with potential to deliver superior outcomes for people with incomplete response to CGRP-targeted therapies. The company's programs were discovered by Paragon Therapeutics. Mentari is based in Waltham, MA. For more information, visit mentaritx.com.Forward Looking StatementsCertain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to InMed's and Mentari's expectations, hopes, beliefs, intentions or strategies regarding the proposed merger, the Private Placement, and the combined company's future, pipeline and business including, without limitation, statements regarding the expected timing and completion of the proposed merger and the Private Placement, the anticipated ownership structure of the combined company, the expected benefits, opportunities and market potential of the proposed transaction, the combined company's ability to achieve the expected benefits or opportunities with respect to its product candidates, including whether MT-001 and MT-002 will achieve clinical proof of concept, demonstrate superior efficacy or potency, achieve convenient dosing, address unmet need in CGRP inadequate responders, or achieve regulatory approval and statements made herein with respect to (i) a potential distribution or dividend (if any) (A) payable upon a Parent Legacy Transaction, and (B) to the extent closing net cash exceeds certain thresholds described in the Agreement, and (ii) the contingent value rights entitling the Holders to proceeds (if any) from a Parent Legacy Transaction received post-closing. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the combined company will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond InMed's, Mentari's or the combined company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to: the risk that the proposed merger and the Private Placement may not be completed on the anticipated timeline or at all; the failure to satisfy the conditions to closing, including obtaining the requisite approvals of the stockholders of each company and the effectiveness of the registration statement to be filed with the SEC in connection with the proposed merger; the risk that the Private Placement may not close or may not result in the anticipated gross proceeds; the outcome of preclinical studies and clinical trials; regulatory approval processes; the combined company's ability to successfully develop and commercialize its product candidates; competition in the migraine treatment market; the combined company's reliance on third parties; protection of intellectual property; and the combined company's need for substantial additional funding. Should one or more of these risks or uncertainties materialize, or should any of InMed's, Mentari's or the combined company's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and in InMed's filings with the SEC. InMed, Mentari and the combined company do not undertake or accept any duty to make any updates or revisions to any forward-looking statements, except as required by law.Important Information About Investigational Product CandidatesThis press release concerns drug candidates that are under preclinical and clinical investigation, and which have not yet been approved by the U.S. Food and Drug Administration. These are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated.No Offer or SolicitationThis press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any proxy, vote, consent or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities to be sold in the Private Placement are being offered in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.Important Additional Information About the Proposed Transaction Will Be Filed with the SECIn connection with the proposed merger, InMed intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a proxy statement/prospectus relating to the proposed transaction. This press release is not a substitute for the registration statement, proxy statement/prospectus or any other document that InMed may file with the SEC in connection with the proposed transaction.INVESTORS AND SECURITY HOLDERS OF INMED AND MENTARI ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT INMED, MENTARI, THE PROPOSED TRANSACTION AND RELATED MATTERS.Investors and security holders will be able to obtain free copies of the registration statement, proxy statement/prospectus and other documents filed by InMed with the SEC through the website maintained by the SEC at www.sec.gov and on the Investors section of InMed's website.Participants in the SolicitationInMed, Mentari and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from InMed's stockholders in connection with the proposed transaction. Information about InMed's directors and executive officers, including a description of their interests in InMed, is contained in InMed's most recent Annual Report on Form 10-K and subsequent reports filed with the SEC. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the proposed transaction, including a description of their direct or indirect interests, by security holdings or otherwise, will be included in the registration statement and proxy statement/prospectus when filed with the SEC.Media ContactLia Dangelico
Deerfield Group
lia.dangelico@deerfieldgroup.comInvestor Contact
Colin Clancy
Vice President, Investor Relations
and Corporate Communications, InMed Pharmaceuticals Inc.
T:  +1.604.416.0999
E:   ir@inmedpharma.comCorrection: An update has been made to the last sentence of paragraph 11. View original content to download multimedia:https://www.prnewswire.com/news-releases/inmed-pharmaceuticals--mentari-therapeutics-announce-merger-to-advance-migraine-prevention-therapies-302776112.htmlSOURCE InMed Pharmaceuticals Original: /C O R R E C T I O N -- InMed Pharmaceuticals/

InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM)May 19, 2026 10:37 AM
IH Market News The merger shifts InMed toward migraine prevention therapies while a large private financing is expected to fund operations through key clinical milestones. Key Investor Takeaways InMed Pharmaceuticals (NASDAQ:INM) announced an all-stock merger with private biotech company Mentari Therapeutics focused on migraine prevention therapies. The transaction includes an oversubscribed $290 million private placement expected to fund the combined company through 2028. Mentari’s lead pipeline includes anti-PACAP and anti-CGRP/PACAP bispecific antibody programs targeting unmet needs in migraine prevention. Existing InMed shareholders are expected to own approximately 1.51% of the combined company after closing. The merger significantly changes InMed’s strategic direction, shifting focus away from cannabinoid-based programs toward neurological disease therapeutics. Why INM Stock Is In Focus InMed Pharmaceuticals, Inc. (NASDAQ:INM) announced a definitive merger agreement with privately held Mentari Therapeutics in an all-stock transaction that will create a new Nasdaq-listed migraine-focused biotechnology company.Following completion of the transaction, the combined company will operate under the name Mentari Therapeutics and trade under a new Nasdaq ticker symbol.The merger combines Mentari’s migraine prevention pipeline with InMed’s existing public company infrastructure.The announcement also included a concurrent oversubscribed private placement expected to generate approximately $290 million in gross proceeds. According to the companies, the financing is expected to fund operations through 2028 and beyond anticipated key clinical data readouts.Mentari’s lead pipeline includes MT-001, an anti-PACAP monoclonal antibody, and MT-002, a potentially first-in-class anti-CGRP and anti-PACAP bispecific antibody.The companies said MT-001 is expected to reach first-in-human regulatory filings in mid-2026, while MT-002 is expected to enter regulatory filing stages in the first quarter of 2027.Management highlighted the commercial opportunity tied to migraine treatment limitations, noting that many patients do not achieve sufficient symptom reduction with currently approved anti-CGRP therapies.“This merger with Mentari represents an excellent opportunity for InMed shareholders to participate in the development of an exciting new drug pipeline with significant therapeutic and commercial potential,” said Eric A. Adams, President and CEO of InMed.“This transaction provides us with the capital and public market infrastructure to aggressively compete in what we believe will be the next era of migraine prevention,” said Julie Bruno, Chair of Mentari’s board. Why This Matters For Investors The transaction is significant because it effectively transforms InMed from a cannabinoid-focused drug developer into a migraine therapeutics company backed by substantial institutional financing.The $290 million financing package may reduce near-term funding concerns that often weigh on clinical-stage biotechnology companies, particularly given management’s expectation that capital will support operations through multiple clinical milestones.The migraine market also represents a substantially larger commercial opportunity than InMed’s prior pipeline focus, especially as newer mechanisms such as PACAP inhibition gain attention following recent industry clinical validation.At the same time, the structure of the transaction may raise questions for existing shareholders because pre-merger InMed investors are expected to own only approximately 1.51% of the combined company following closing.Investors may also focus on execution risk tied to early-stage clinical development, future regulatory progress and whether Mentari’s programs can demonstrate advantages over existing migraine therapies.The presence of large healthcare-focused institutional investors participating in the financing may also influence sentiment around the transaction and future development prospects. What To Watch Next Investors will likely monitor: Completion of the merger transaction expected in the second half of 2026 Regulatory filing timelines for MT-001 and MT-002 Future clinical data releases tied to anti-PACAP therapies Progress toward Phase 1 and Phase 2 studies Final shareholder approval and SEC registration filings Further details regarding the combined company’s Nasdaq ticker transition Any monetization or disposition of InMed legacy assets and programs InMed Pharmaceuticals stock price Original: InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM)

InMed Pharmaceuticals Amends Preferred Investment OptionsMay 19, 2026 6:00 AM
NewsfileVancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into an amending agreement with Armistice Capital Master Fund Ltd. ("Armistice") in respect of certain outstanding preferred investment options held by Armistice.As previously reported, pursuant to the terms of certain preferred investment options dated October 26, 2023 issued to Armistice (the "Armistice Preferred Investment Options"), the Company provided Armistice with the right to subscribe for and purchase from the Company up to 278,761 common shares in the capital of the Company at an exercise price per common share of $16.60, subject to adjustment (the "Armistice Exercise Price"). The Company has entered into an amending agreement with Armistice in respect of the Armistice Preferred Investment Options to amend the Armistice Exercise Price from $16.60 to $0.80. The Armistice Preferred Investment Options were offered in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder. No assurance can be given that any of the Armistice Preferred Investment Options will be exercised.For further information, please see the Company's filings with the Securities and Exchange Commission, including the Company's Current Reports on Form 8-K filed with the Securities and Exchange Commission from time to time.About InMedInMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com. Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.comCautionary Note Regarding Forward-Looking Information:This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about the exercise of the Armistice Preferred Investment Options prior to their expiration.With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, InMed's Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov.All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297903 Original: InMed Pharmaceuticals Amends Preferred Investment Options

InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business UpdateMay 6, 2026 6:00 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - May 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the third quarter of the fiscal year 2026 which ended March 31, 2026.The Company's full financial statements and related MD&A for the third quarter ended March 31, 2026, are available at www.inmedpharma.com, www.sedarplus.com and at www.sec.gov."During the quarter, InMed reported additional preclinical data that further support the development of INM-901 for Alzheimer's disease through its targeting of neuroinflammation. Data from advanced human brain organoid systems demonstrated anti-neuroinflammatory effects consistent with findings observed across multiple in vivo and ex vivo studies," commented Eric A. Adams, InMed President and CEO.Business Update INM-901: Targeting the Modulation of Neuroinflammation in Alzheimer's disease
InMed's proprietary, disease-modifying, small molecule drug candidate INM-901 is a preferential signaling agonist of the CB1/CB2 receptors and continues to advance as a potential treatment for Alzheimer's disease with a primary focus on modulating neuroinflammation. During the quarter, InMed announced preclinical data demonstrating the effects of INM-901 in reducing neuroinflammation in 3D human brain organoid models of Alzheimer's disease.The in vitro human organoid models represent some of the closest approximations to human brain tissue currently available, incorporating a complex cellular environment relevant to neurodegenerative disease. The organoids are composed of neurons, astrocytes, vascular cells and feature microglia, the brain's resident immune cells, and can be used to bridge the gap between traditional animal models and human clinical trials.INM-901 was evaluated in two distinct human 3D organoid models: a general model of neuroinflammation induced with lipopolysaccharide ("LPS") and interferon-gamma ("IFN-?"); and, Stem Pharm's proprietary neuroinflammation Alzheimer's disease model with specific features observed in Alzheimer's disease patients.Key Observations included:INM-901 demonstrated significant reduction in neuroinflammation in Stem Pharm's LPS-induced model and in their Alzheimer's disease model. A dose-dependent reduction of key pro-inflammatory markers such as IL-6 and IL-8 was seen in both neuroinflammation models.Effects align with prior findings from an in vivo Alzheimer's model and an ex vivo LPS-induced neuroinflammation model.Provides supportive evidence of mechanistic translation from animal models to human tissue systems.The consistency of INM-901's anti-inflammatory effects across in vivo animal models, ex vivo systems and now human 3D brain organoids provide increasing confidence in the compound's potential to translate into clinical benefit in humans with neuroinflammatory conditions.Discontinued Operations
On March 4, 2026, the Company's board of directors ratified, confirmed and approved the decision of the board members of BayMedica to wind down and exit BayMedica's commercial operations business segment ("Commercial Operations"), which is the only revenue-generating commercial operations of the Company. BayMedica intends to substantially complete the wind down and exit prior to the end of its fiscal year ending June 30, 2026. During the interim period leading to the completion of operational wind down, BayMedica will continue its commercial operations including sales, marketing, limited manufacturing, and logistics.Financial CommentaryFollowing the classification of the Commercial segment as discontinued operations, the Company has one reportable segment that constitutes consolidated results consisting of its operations. Unless otherwise noted, all activities and amounts reported in the following notes relate to the continuing operations of the Company and exclude activities and amounts related to discontinued operations.For the three months ended March 31, 2026, the Company reported a net loss of $3.0 million, compared to a net loss of $2.1 million in the same period the previous year. The increase was largely driven by higher expenses related to pharmaceutical research and development activities, as well as financing costs.Pharmaceutical research and development for continuing operations were $1.0 million for the three months ended March 31, 2026, compared with $0.4 million for the three months ended March 31, 2025. The increase was primarily due to an increase in external contractors relating to our INM-901 program General and administrative expenses for continuing operations were $1.7 million for the three months ended March 31, 2026, compared to $1.6 million the same period the previous year. The increase resulted primarily from a combination of changes including lower accounting fees, share-based payments fees, and shareholder communication fees.As of March 31, 2026, the Company's cash, cash equivalents and short-term investments were $5.2 million, which compares to $10.8 million on June 30, 2025. The Company reported no revenue from continuing operations for the period. The discontinued commercial operations generated revenue of $0.7 million during the period; however, its results are classified as discontinued operations and are presented separately from continuing operations.Table 1. Consolidated Balance Sheet
Expressed in U.S. Dollars
March 31, June 30,
2026 2025
Unaudited (As restated)$ $ASSETS


 


Current


 


Cash and cash equivalents
5,158,932
 
10,743,430
Short-term investments
41,625
 
43,384
Prepaids and other current assets
617,211
 
319,547
Current assets of discontinued operations
1,070,313
 
1,760,918
Total current assets
6,888,081
 
12,867,279
  
 
 
 
Non-Current
 
 
 
Property, equipment and ROU assets, net
642,884
 
992,199
Intangible assets, net
1,498,473
 
1,620,562
Other assets
104,368
 
100,000
Total Assets
9,133,806
 
15,580,040
  
 
 
 
LIABILITIES AND SHAREHOLDERS' EQUITY
 
 
 
Current
 
 
 
Accounts payable and accrued liabilities
1,011,551
 
1,230,845
Current portion of lease obligations
389,381
 
435,507
Current liabilities of discontinued operations
810,334
 
173,438
Total current liabilities
2,211,266
 
1,839,790
  
 
 
 
Non-current
 
 
 
Lease obligations, net of current portion
30,766
 
305,755
Total Liabilities
2,242,032
 
2,145,545
Commitments and Contingencies (Note 9)
 
 
 
  
 
 
 
Shareholders' Equity
 
 
 
Common shares, no par value, unlimited authorized shares: 3,314,063 and 2,002,186 as of March 31, 2026 and June 30, 2025, respectively, issued and outstanding
92,578,071
 
91,221,174
Additional paid-in capital
38,144,484
 
39,322,644
Accumulated deficit
(123,959,350) 
(117,237,892)Accumulated other comprehensive income
128,569
 
128,569
Total Shareholders' Equity
6,891,774
 
13,434,495
Total Liabilities and Shareholders' Equity
9,133,806
 
15,580,040
 Table 2. Consolidated Statements of Operations
Expressed in U.S. Dollars
For the Three Months Ended For the Nine Months Ended
March 31, March 31,
2026 2025 2026 2025
$ $ $ $Operating Expenses


 


 


 


Research and development
1,022,630
 
425,370
 
2,222,732
 
2,243,948
General and administrative
1,742,016
 
1,584,393
 
4,304,323
 
4,155,493
Amortization and depreciation
51,707
 
51,706
 
156,912
 
158,289
Foreign exchange loss
23,168
 
22,165
 
62,026
 
50,608
Total operating expenses
2,839,521
 
2,083,634
 
6,745,993
 
6,608,338
  
 
 
 
 
 
 
 
Other Income (Expense)
 
 
 
 
 
 
 
Interest and other income
47,770
 
16,565
 
215,914
 
104,195
Finance expense
-
 
-
 
-
 
(351,549)  
 
 
 
 
 
 
 
Net loss from continuing operations before taxes
(2,791,751) 
(2,067,069) 
(6,530,079) 
(6,855,692)Income tax expense
-
 
-
 
-
 
-
Net loss from continuing operations
(2,791,751) 
(2,067,069) 
(6,530,079) 
(6,855,692)  
 
 
 
 
 
 
 
Discontinued operations:
 
 
 
 
 
 
 
Income (Loss) from discontinued operations
(174,585) 
(53,861) 
(191,379) 
481,870
Income tax benefit
-
 
-
 
-
 
-
Loss from discontinued operations
(174,585) 
(53,861) 
(191,379) 
481,870


 
 
 
 
 
 
 
Net Loss
(2,966,336) 
(2,120,930) 
(6,721,458) 
(6,373,822)  
 
 
 
 
 
 
 
Net loss per share for the period
 
 
 
 
 
 
 
Basic and diluted:
 
 
 
 
 
 
 
Continuing operations
(0.69) 
(1.89) 
(1.64) 
(8.53)Discontinued Operations
(0.04) 
(0.05) 
(0.05) 
0.6
Net loss per share attributable to Common Stockholders?–?basic and diluted
(0.73) 
(1.94) 
(1.69) 
(7.93)Weighted average outstanding common shares
 
 
 
 
 
 
 
Basic and diluted
4,048,209
 
1,095,973
 
3,985,313
 
803,909
 Table 3. Consolidated Statements of Cash Flows
Expressed in U.S. Dollars
For the Nine Months Ended March 31,
2026
 2025

$
 $
Cash provided by (used in):

 

  

 

Operating Activities

 

Net loss
(6,721,458) 
(6,373,822)Items not requiring cash:
 
 
 
Amortization and depreciation
156,912
 
160,087
Share-based compensation
84,240
 
92,577
Amortization of right-of-use assets
291,245
 
243,555
Unrealized foreign exchange loss
27,730
 
44,876
Changes in operating assets and liabilities:
 
 
 
Prepaids and other currents assets
(294,825) 
(61,581)Other non-current assets
(4,368) 
-
Accounts payable and accrued liabilities
(218,577) 
(349,399)Lease obligations
(327,395) 
(315,221)Operating cash flow used by discontinued operations
1,327,501
 
570,483
Total cash used in operating activities
(5,678,995) 
(5,988,445)  
 
 
 
Investing Activities
 
 
 
Sale of short-term investments
41,667
 
40,039
Purchase of short-term investments
(41,667) 
(40,039)Total cash used in investing activities
-
 
-
  
 
 
 
Financing Activities
 
 
 
Proceeds from the private placement
231,675
 
4,361,220
Share issuance costs
(137,178) 
(264,559)Total cash provided by financing activities
94,497
 
4,096,661
Decrease in cash and cash equivalents during the period
(5,584,498) 
(1,891,784)Cash and cash equivalents beginning of the period
10,743,430
 
6,571,610
Cash and cash equivalents end of the period
5,158,932
 
4,679,826
  
 
 
 
SUPPLEMENTARY CASH FLOW INFORMATION:
 
 
 
Cash paid during the period for:
-
 
-
Income taxes$-
 $-
Interest$-
 $-
  
 
 
 
SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
 
 
 
Recognition of Right-of-use asset and corresponding operating lease$-
 $187,223
 About InMedInMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com. Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.comCautionary Note Regarding Forward-Looking Information:This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about; the potential efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901; preclinical data demonstrating the effects of INM-901 in reducing neuroinflammation in 3D human brain organoid models of Alzheimer's disease. demonstrated significant reduction in neuroinflammation in Stem Pharm's LPS-induced model and in their Alzheimer's disease model.With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, InMed's Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov.All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/296317 Original: InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

InMed Pharmaceuticals Amends Preferred Investment OptionsApril 27, 2026 5:30 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - April 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into amending agreements in respect of preferred investment options previously entered into with each of Sabby Volatility Warrant Master Fund, Ltd. ("Sabby") and certain affiliates of H.C. Wainwright & Co., LLC (the "Wainwright Parties").As previously reported: pursuant to the terms of the preferred investment options dated October 26, 2023 and June 26, 2025 (together, the "Sabby Preferred Investment Options"), the Company provided Sabby with the right to subscribe for and purchase from the Company, in the aggregate, up to 2,151,478 common shares in the capital of the Company (on a post-consolidation basis) at an exercise price per common share of $2.436, subject to adjustment (the "Sabby Exercise Price"); andpursuant to the terms of the preferred investment options dated November 21, 2022, October 26, 2023 and June 26, 2025 issued to the Wainwright Parties (collectively, the "Wainwright Preferred Investment Options", and together with the Sabby Preferred Investment Options, the "Preferred Investment Options"), the Company provided the Wainwright Parties with the right to subscribe for and purchase from the Company, in the aggregate, up to 153,236 common shares in the capital of the Company (on a post-consolidation basis) at exercise prices per common share of $82.50, $20.75 and $3.2013 (in each case, on a post-consolidation basis), respectively, subject to adjustment in each case (collectively, the "Wainwright Exercise Prices").The Company has entered into: (i) an amending agreement with Sabby in respect of the Sabby Preferred Investment Options to amend the Sabby Exercise Price to $0.80; and (ii) amending agreements with the Wainwright Parties in respect of the Wainwright Preferred Investment Options to amend the Wainwright Exercise Prices in the Wainwright Preferred Investment Options to $0.80.Each of the Preferred Investment Options were offered in private placements pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Regulation D promulgated thereunder. No assurance can be given that any of the Preferred Investment Options will be exercised.For further information, please see the Company's filings with the Securities and Exchange Commission, including the Company's Current Reports on Form 8-K filed with the Securities and Exchange Commission from time to time.About InMedInMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. Together with our subsidiary BayMedica, we are a global leader in the manufacturing, development and commercialization of products based on rare cannabinoids and their proprietary, small molecule drug analogs. For more information, visit www.inmedpharma.com. Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.comCautionary Note Regarding Forward-Looking Information:This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about the exercise of the Preferred Investment Options prior to their expiration.With respect to the forward-looking information contained in this news release, InMed has made numerous assumptions regarding, among other things: the ability to obtain all necessary regulatory approvals on a timely basis, or at all; and continued economic and market stability. While InMed considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, InMed's Quarterly Report on Form 10-Q and other filings with the Security and Exchange Commission on www.sec.gov.All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/294412
Original: InMed Pharmaceuticals Amends Preferred Investment Options

InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price ComplianceMarch 27, 2026 5:05 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - March 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced the Company received a written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") dated March 27, 2026, notifying it that the closing bid price of the Company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) during the February 11, 2026 to March 26, 2026 period.The notice has no immediate impact on the listing of the Company's common shares, which will continue to trade on The Nasdaq Capital Market subject to the Company's continued compliance with the other listing requirements of The Nasdaq Capital Market. In accordance with applicable Nasdaq procedures, the Company has a period of 180 calendar days following the receipt of the written notice mentioned above to cure the deficiency and regain compliance. To regain compliance, the closing bid price of the common shares of the Company must meet or exceed $1.00 per share for at least 10 consecutive business days during the 180-calendar day compliance period. The common shares of the Company will continue to trade under the symbol "INM". The Company intends to monitor the closing share price for its common shares and explore available options to regain compliance.In the event the Company does not evidence compliance with the minimum bid price requirement during the 180-day grace period, the Company may be eligible for an additional 180 calendar day grace period. To qualify, the Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for The Nasdaq Capital Market, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period, by effecting a reverse stock split, if necessary, to Nasdaq. If it appears to the staff of Nasdaq that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, the Company will not be entitled to an additional 180 calendar days grace period and Nasdaq sill provide notice to the Company that its securities will be subject to delisting. If the Company does not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, it is expected that Nasdaq would notify the Company that its common shares are subject to delisting. If the Company is notified by Nasdaq that its securities are subject to delisting, the Company may appeal such determination to a Nasdaq Hearings Panel (the "Panel") but the Company's securities would be automatically suspended from trading on Nasdaq pending the completion of the appeal process. There can be no assurance that any such appeal would be successful or that the Company would be able to evidence compliance with the terms of any extension that may be granted by the Panel.About InMed: InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small-molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.comCautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: those relating to the Company's ability to regain compliance with the Nasdaq Capital Market minimum bid price requirement, including, without limitation, by effecting one or more stock splits if necessary; the impact of Nasdaq's notice on the listing of the Company's common shares on Nasdaq; and the Company's ability to meet the minimum stockholders' bid requirement for continued listing under Nasdaq listing rules or the success of any proposed appeal to the panel.Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/290289
Original: InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease ProgramMarch 23, 2026 7:30 AM
NewsfileHuman Organoid Data Supports the Therapeutic Rationale for INM-901 Program Ahead of Human Clinical TrialsConsistent Anti-Inflammatory Effects Demonstrate Translation from Animal Models to Three-Dimensional Human Brain Tissue SystemsVancouver, British Columbia--(Newsfile Corp. - March 23, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors, today announced new preclinical data demonstrating the effects of INM-901 in reducing neuroinflammation in 3D human brain organoid models of Alzheimer's disease.These studies, conducted in collaboration with Stem Pharm, Inc. ("Stem Pharm") using their proprietary platform of human neuro-immune organoids, represent a key step in translating prior animal model results for INM-901 into a human-relevant system, helping to de-risk the INM-901 program ahead of a first-in-human clinical trial.The in vitro human organoid models represent some of the closest approximations to human brain tissue currently available, incorporating a complex cellular environment relevant to neurodegenerative disease. The organoids are composed of neurons, astrocytes, vascular cells and feature microglia, the brain's resident immune cells, and can be used to bridge the gap between traditional animal models and human clinical trials. INM-901 was evaluated in two distinct human 3D organoid models: a general model of neuroinflammation induced with lipopolysaccharide ("LPS") and interferon-gamma ("IFN-?"); and, Stem Pharm's proprietary neuroinflammation Alzheimer's disease model with specific features observed in Alzheimer's disease patients.Key Observations:INM-901 demonstrated significant reduction in neuroinflammation in Stem Pharm's LPS-induced model and in their Alzheimer's disease model. A dose-dependent reduction of key pro-inflammatory markers such as IL-6 and IL-8 was seen in both neuroinflammation models.Effects align with prior findings from an in vivo Alzheimer's model and an ex vivo LPS-induced neuroinflammation model.Provides supportive evidence of mechanistic translation from animal models to human tissue systems.The consistency of INM-901's anti-inflammatory effects across in vivo animal models, ex vivo systems and now human 3D brain organoids provide increasing confidence in the compound's potential to translate into clinical benefit in humans with neuroinflammatory conditions.Dr. Eric Hsu, InMed SVP of Preclinical Research and Development, commented, "These results represent an important milestone for INM-901. We have now demonstrated consistent anti-neuroinflammatory effects across multiple in vivo and ex vivo studies, and, importantly, these findings have now been translated into advanced human brain organoid systems. This systematic validation significantly de-risks the program and strengthens our confidence as we advance INM-901 toward human clinical trials."Key Datasets impacting Anti-Neuroinflammation to date:In a long-term mouse model mimicking Alzheimer's disease, INM-901 significantly reduced inflammatory biomarkers IFN-?, TNF-a, IL-1ß, KC-GRO, IL-2 and neurodegenerative marker neurofilament light chain ("NfL").INM-901 significantly reduced inflammasome activation and multiple pro-inflammatory cytokines, including NLRP3, IL-1ß, IL-6, IL-2 and KC-GRO in an LPS-induced neuroinflammation ex vivo model, demonstrated anti-inflammatory effects independent of amyloid-beta or tau pathology.Reduction of neuroinflammation in 3D human brain organoid models of Alzheimer's disease.Next Steps for the INM-901 Program for Alzheimer's DiseaseConduct a pre-IND meeting with the U.S. Food and Drug Administration in Q3/2026.Continue to execute on IND-enabling pharmacology and toxicology studies.Continued development and scale-up of drug substance and product manufacturing activities to support IND enabling studies and submission.Engage regulatory/clinical experts in neurodegenerative diseases to map out topline clinical design for first-in-human clinical trials for the INM-901.Subject to regulatory feedback and completion of IND-enabling activities, the Company targets submission of an IND and initiation of a Phase 1 clinical trial in 2027.Why Neuroinflammation Matters in Alzheimer's DiseaseRecent drug development efforts in Alzheimer's disease have largely focused on amyloid plaque and tau pathology, leading to the first disease-modifying therapies in recent years. However, increasing attention is being directed toward neuroinflammation as a key underlying driver of disease progression. Studies presented at the recent global Alzheimer's conferences highlighted the relationship between inflammatory biomarkers and the risk of Alzheimer's disease and other dementias, underscoring the growing importance of targeting inflammation. Current research has demonstrated significant progress in understanding disease mechanisms and clinical interventions, with inflammation emerging as a critical factor influencing long-term patient outcomes. As such, neuroinflammation is increasingly recognized as a strategic therapeutic target for next-generation Alzheimer's treatments. About Stem Pharm, Inc.Stem Pharm is developing next-generation neurologic drugs using a human-first approach. Stem Pharm's proprietary drug discovery platform is based on human 3D neuro-immune organoids that feature microglia and model neuroinflammation, which play a critical role in many neurological diseases. The company applies this platform to discover and validate disease targets and therapeutics for its internal programs in Alzheimer's disease, epilepsy, and brain cancer as well as for its biopharma partners' therapeutic programs. Stem Pharm is based in Madison, WI, a hub for innovative stem cell and biosciences research. For more information, visit stempharm.com. About InMed: InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small-molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.comCautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors; the potential efficacy of INM-901; INM-901's ability to treat Alzheimer's; marketability and uses for INM-901; reducing neuroinflammation in 3D human brain organoid models; demonstrating consistent anti-neuroinflammatory effects across multiple in vivo and ex vivo studies, and being translating into advanced human brain organoid systems; the advancement of CMC activities; the planning of GLP-enabling studies and the preparation of an IND submission the further development; planning for a pre-IND meeting in Q3 2026; engaging regulatory / clinical experts to map out topline clinical design for first in human clinical trials for the INM-901; and, targeting submission of an IND and initiation of a Phase 1 clinical trial in 2027.Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/289438
Original: InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

INM............................https://stockcharts.com/sc3/ui/?s=INM&p=W&b=5&g=0&id=p86431144783

InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical TrialMarch 9, 2026 7:30 AM
NewsfileAdvancing Alzheimer's and Age-Related Macular Degeneration Programs Toward FDA Engagement and IND-Enabling ActivitiesTargeting Initiation of Phase 1 Clinical Trial in Alzheimer's Disease in 2027Vancouver, British Columbia--(Newsfile Corp. - March 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, today provides a pharmaceutical development outlook for 2026. "Over the last several quarters, we made meaningful scientific and operational progress across our pipeline, particularly with INM-901, generating data that fundamentally strengthened its scientific rationale and strategic positioning in the Alzheimer's segment. These results support a differentiated approach to Alzheimer's disease that extends beyond single-target strategies. We further refined the program's direction and reinforced our conviction that targeting neuroinflammation is critical to addressing Alzheimer's disease progression," commented Eric A. Adams, InMed President and CEO."Looking ahead in 2026, our primary focus is executing activities toward a pre-IND meeting with the FDA in Q3 to discuss the INM-901 program, which we believe will be a key inflection point as we work toward IND submission and initiation of a Phase 1 clinical trial in 2027. In parallel, we will continue developing INM-089 and plan for a pre-IND meeting in Q4 2026."INM-901 Program OutlookINM-901 is a proprietary, orally bioavailable, disease-modifying small molecule drug candidate that is a preferential CB1/CB2 signaling agonist and can cross the blood-brain barrier with a specific focus on treating neuroinflammation in Alzheimer's disease. InMed believes INM-901 is uniquely positioned within the evolving Alzheimer's disease treatment landscape as increasing scientific consensus suggests that the disease is driven by multiple, interrelated biological pathways, rather than a single pathogenic mechanism.InMed has generated preclinical evidence supporting that INM-901 exerts a therapeutic effect by directly attenuating neuroinflammation, which functions as a primary pathogenic driver for the Alzheimer's disease progression rather than a secondary or a reactive effect. Additional data on neuroprotection and neuritogenesis of INM-901 demonstrated a multifactorial mechanism of action, engaging several complementary pathways critical to mitigate neurodegeneration. By clarifying its focus, InMed strengthened the clinical and commercial rationale for INM-901 and positioned the program to pursue the most efficient and impactful path forward.Scientific and Development Progress in 2025 include:Key Anti-Neuroinflammation ProgressIn 5xFAD mouse model, INM-901 significantly reduced inflammatory biomarkers IFN-?, TNF-a, IL-1ß, KC-GRO, IL-2 and neurodegenerative marker neurofilament light chain (NfL).INM-901 significantly reduced inflammasome activation and multiple pro-inflammatory cytokines, including NLRP3, IL-1ß, IL-6, IL-2 and KC-GRO in an LPS induced neuroinflammation model, demonstrated anti-inflammatory effects independent of amyloid-beta or tau pathology.Progress Across Additional Mechanisms Within Alzheimer's PathologyNeuroprotection: INM-901 significantly reduces amyloid beta-induced cell death.?Neuronal Regeneration: INM-901 promotes neurite outgrowth, indicating its ability to enhance neuronal connectivity and function.?Behavioral Improvements: In preclinical studies, INM-901 demonstrates positive trends in cognitive function, anxiety-related behavior, and sensory responsiveness?.Bioavailability: In large animal model, INM-901 oral formulation achieved anticipated therapeutic levels of systemic exposure?.Molecular Validation: mRNA data aligns with behavioral findings, supporting observed improvements in cognition, memory and neurogenesis.Additional Drug Development ProgressionInitiation of the dose-ranging and exposure assessments supporting advancement toward IND-enabling studies.Progress in drug substance and drug product development, including formulation development and scale up to support dose ranging and future GLP studies. Advancement of drug product and drug substance analytical methods and stability assessments consistent with regulatory expectations.Initiation of a regulatory and clinical development framework to support first-in-human evaluation.2026 Development Priorities for INM-901 include:Conduct a pre-IND meeting with the U.S. Food and Drug Administration in Q3/2026.Continue to execute on IND-enabling pharmacology and toxicology studies.Continued development and scale up of drug substance and product manufacturing activities to support IND enabling studies and submission.Engage regulatory / clinical experts to map out topline clinical design for first in human clinical trials for the INM-901. Subject to regulatory feedback and completion of IND-enabling activities, the Company targets submission of an IND and initiation of a Phase 1 clinical trial in 2027.As we move forward, the progress achieved to date reinforces our confidence in INM-901 and in our strategic direction with a disciplined focus on neuroinflammation with a clear development plan. We believe we are positioned to advance INM-901 efficiently and deliver meaningful long-term value for shareholders.INM-089 Program OutlookINM-089 is a small molecule drug candidate being studied for its potential as a treatment for dry age-related macular degeneration.Scientific and development progress and plans include:Generation of data supporting continued evaluation of therapeutic potential.Completion of preclinical studies, including dose-ranging assessment, demonstrating dose proportionality and pharmacologically relevant concentration following dosing.Drug substance and drug product process in place to support IND enabling studies, with further optimization expected in advance of IND submission.Planning for a pre-IND meeting with the FDA in Q4 2026.About InMed: InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.comCautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors; the potential efficacy of INM-901; INM-901's ability to treat Alzheimer's; marketability and uses for INM-901; the advancement of chemistry, manufacturing, and controls (CMC) activities; the planning of GLP-enabling studies and the preparation of an IND submission the further development; planning for a pre-IND meeting in Q3 2026; engaging regulatory / clinical experts to map out topline clinical design for first in human clinical trials for the INM-901; targeting submission of an IND and initiation of a Phase 1 clinical trial in 2027; potential efficacy, and marketability of INM-089 for dry age-related macular degeneration; preparing for a pre-IND meeting with the FDA in Q4 2026 for INM-089.Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/287694
Original: InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development PipelineMarch 6, 2026 5:04 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - March 6, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, today announced an update regarding BayMedica LLC ("BayMedica"), a wholly owned subsidiary of the Company, in light of ongoing uncertainty surrounding U.S. federal legislation.As previously announced, H.R. 5371, the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026" (the "Act") in its current form and without further amendment, will have a material negative impact on BayMedica. Specifically, certain aspects of BayMedica's commercial business and its inventory of rare, non-intoxicating cannabinoids would be prohibited under the Act if it becomes effective as planned on November 12, 2026.On March 4, 2026, after considering all reasonably available options and a broader strategic assessment, the Company's board of directors (the "Board") ratified, confirmed and approved the decision of the board of directors of BayMedica to wind down and exit BayMedica's commercial operations business segment ("commercial operations"). BayMedica intends to substantially complete the wind down and exit prior to the end of its fiscal year ending June 30, 2026. During the interim period leading to the completion of operational wind down, BayMedica will continue its commercial operations including sales, marketing, limited manufacturing, and logistics. Following the wind down of commercial operations, the Company will focus exclusively on advancing its core drug development programs, including INM-901 for Alzheimer's disease and INM-089 for dry age-related macular degeneration, towards IND filings and initial human clinical trials. The Company intends to provide shareholders with an update on its pharmaceutical pipeline in the near term.Eric A. Adams, Chief Executive Officer of InMed, commented, "Following an extensive evaluation of BayMedica's commercial outlook amid increasing regulatory uncertainty, BayMedica's leadership determined to wind down its commercial activities. After careful review, the Board agreed that this strategic step is warranted given the current legislative environment and, further, enables InMed to focus its full internal resources on the development and advancement of our proprietary pharmaceutical drug development programs, which have the greatest potential to deliver long-term shareholder value."Operational and Financial Impact The wind down of BayMedica's commercial operations will be executed in an orderly manner designed to minimize disruption to customers, suppliers, and employees. BayMedica's management team is developing a transition plan that will be communicated to affected stakeholders, and the Company currently expects the process to be completed within the coming months. BayMedica is expected to incur severance and other employee-related costs of approximately $550,000 and expects to incur additional related expenditures of approximately $120,000 through the end of this fiscal year ending June 30, 2026. These expenditures are expected to be partially offset by the profits from the sale of BayMedica's products.The Company has outlined the current financial implications, including unaudited pro forma consolidated financial information, in a Form 8-K filed with the U.S. Securities and Exchange Commission (the "SEC") on March 6, 2026. InMed expects to provide additional updates, as appropriate, in future earnings releases and periodic filings with the SEC.About InMed: InMed Pharmaceuticals is a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.comCautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: developing a pipeline of disease-modifying small molecule drug candidates that target CB1/CB2 receptors, statements about the Act, the impact of the Act on BayMedica, decision of the board members of BayMedica to wind down and exit BayMedica's commercial operations business segment as well as financial and operational impact on the wind-down of BayMedica commercial operations.Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's business is disclosed in InMed's Annual Report on Form 10-K and other filings with the Securities and Exchange Commission on www.sec.gov.All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/286536
Original: InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business UpdateFebruary 11, 2026 5:23 PM
NewsfileVancouver, British Columbia--(Newsfile Corp. - February 11, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical drug development company focused on developing a pipeline of proprietary small-molecule drug candidates for diseases with high unmet medical needs, today reports financial results for its second quarter of fiscal year 2026, which ended December 31, 2025.The Company's full financial statements and related MD&A for the second quarter ended December 31, 2025 are available at www.inmedpharma.com, www.sedarplus.ca and at www.sec.gov.Eric A. Adams, InMed Chief Executive Officer, commented, "We are pleased with the steady progress across our pharmaceutical pipeline as we look ahead to pursuing pre-IND meetings with the FDA in 2026. In our INM-901 program, compelling data from the preclinical studies demonstrated a significant reduction in key neuroinflammatory markers, reinforcing neuroinflammation as the central focus of our drug development activities."Business Update - Pharmaceutical Development ProgramsINM-901: Targeting the Modulation of Neuroinflammation in Alzheimer's disease
InMed's proprietary, disease-modifying, small molecule drug candidate INM-901 is a preferential signaling agonist of the CB1/CB2 receptors and continues to advance as a potential treatment for Alzheimer's disease with a primary focus on modulating neuroinflammation. During the quarter, InMed announced the successful completion of pharmacokinetic studies in clinically relevant in vivo models for INM-901. This marked the first preclinical study in which the oral formulation of INM-901 was administered in large animals. The results provide additional data in guiding decisions in the design of a human Phase 1 clinical trial program. Over a seven-day dosing period, the studies demonstrated robust bioavailability, achieving what is anticipated to be therapeutic levels of systemic exposure for INM-901. In addition, neurological assessments evaluating general attitude, behavior, and motor function revealed no adverse neural or behavioral effects, reinforcing the compound's favorable profile and supporting its continued advancement toward first-in-human clinical trials.Next development steps:Advancing CMC activities for scale-up and supplyDose ranging studies in two speciesPreparing for a pre-IND meeting with the FDAGLP-enabling studies to support an IND submissionINM-089: Neuroprotection in the treatment of dry age-related macular degeneration ("AMD")
INM-089 is a proprietary, disease-modifying small-molecule drug candidate under investigation for the treatment of dry AMD. INM-089 is an intravitreal ("IVT") injectable formulation, which has been successfully delivered to the targeted area of the eye in preclinical studies at doses up to 10 times the calculated safety margin relative to the intended therapeutic dose. The Company continues to advance preclinical studies demonstrating significant functional and pathological improvements in a dry AMD disease study model. Next development steps:Preparing for a pre-IND meeting with the FDA GLP-enabling studies to support an IND submissionFinancial Commentary:BayMedica's commercial business generated revenues of $0.8 million for the three months ending December 31, 2025, compared to $1.1 million for the same period last year, reflecting a 26% decrease. This decrease is primarily attributed to drop in demand due to the currently pending changes in US legislation (Continuing Resolution and Appropriations Package (H.R. 5371, Section 781)) referenced below. The Company's research and development expenses were $0.6 million for the three months ending December 31, 2025, compared with $0.9 million for the three months ending December 31, 2024. The decrease in research and development expenses was primarily due to reduced spending on external contractors and research supplies, offset in part by an increase in compensation. We expect research and development expenses to increase substantially through the remainder of fiscal year 2026 as the Company advances preclinical work and IND-enabling studies for INM-901.The Company incurred general and administrative expenses of $1.6 million for the three months ended December 31, 2025, compared with $1.7 million for the three months ending December 31, 2024. As of December 31, 2025, the Company's cash, cash equivalents and short-term investments were $7.0 million, which compares to $11.1 million on June 30, 2025. The Company continues to closely monitor expenses while advancing its pharmaceutical pipeline candidates. Based on current forecasts, the Company expects its cash will be sufficient to fund its planned operating expenses and capital expenditure into the fourth quarter of calendar year 2026, depending on the level and timing of BayMedica commercial revenues. As previously reported, U.S. congressional legislation H.R. 5371, the "Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026" (the "Act") was signed into law. The Act, in its current form and without further amendment, will have a material negative impact on BayMedica, a subsidiary of the Company. Specifically, certain aspects of BayMedica's commercial business and its inventory of rare, non-intoxicating cannabinoids would be prohibited under the Act if it comes into force on November 12, 2026. It is unknown to the Company whether the sections of the Act that would impact BayMedica will ultimately go into effect on November 12, 2026, or at all, or if those sections will be replaced, impacted or amended by subsequent acts of U.S. policymakers.BayMedica is evaluating alternative options, but has not set a timetable for the conclusion of its evaluation, nor has it made any definitive decisions related to any potential alternative options at this time. In the meantime, BayMedica is continuing to sell its inventory of rare, non-intoxicating cannabinoids. Without timely, meaningful changes to the Act, we would need to write-off any inventory that BayMedica is unable to sell prior to the Act becoming effective and take other actions, which could include divesting BayMedica's commercial business, if possible, pivoting to other manufacturing techniques, if commercially viable, or discontinuing BayMedica's commercial business, all of which would have a material adverse effect on our business, results of operations and financial condition.Table 1. Consolidated Balance Sheet
Expressed in U.S. Dollars

December 31,

June 30,


2025

2025


Unaudited




$
 $ASSETS





Current





Cash and cash equivalents
6,954,834

11,075,871
Short-term investments
42,675

43,384
Accounts receivable, net
182,967

465,104
Inventories, net
947,898

961,173
Prepaids and other current assets
660,280

321,747
Total current assets
8,788,654

12,867,279


 

 
Non-Current
 

 
Property, equipment and ROU assets, net
764,254

992,199
Intangible assets, net
1,538,576

1,620,562
Other assets
100,000

100,000
Total Assets
11,191,484

15,580,040


 

 
LIABILITIES AND SHAREHOLDERS' EQUITY
 

 
Current
 

 
Accounts payable and accrued liabilities
1,071,871

1,404,283
Current portion of lease obligations
408,122

435,507
Total current liabilities
1,479,993

1,839,790


 

 
Non-current
 

 
Lease obligations, net of current portion
123,827

305,755
Total Liabilities
1,603,820

2,145,545
Commitments and Contingencies (Note 10)
 

 


 

 
Shareholders' Equity
 

 
Common shares, no par value, unlimited authorized shares: 2,804,186 and 2,002,186 as of December 31, 2025 and June 30, 2025, respectively, issued and outstanding
92,046,396

91,221,174
Additional paid-in capital
38,405,713

39,322,644
Accumulated deficit
(120,993,014)

(117,237,892)
Accumulated other comprehensive income
128,569

128,569
Total Shareholders' Equity
9,587,664

13,434,495
Total Liabilities and Shareholders' Equity
11,191,484

15,580,040
 Table 2. Consolidated Statements of Operations
Expressed in U.S. Dollars

For the Three Months Ended

For the Six Months Ended


December 31,

December 31,


2025

2024

2025

2024


$

$

$

$
Sales
820,188

1,111,707

1,940,309

2,376,345
Cost of sales
635,994

650,813

1,352,956

1,422,038
Gross profit
184,194

460,894

587,353

954,307


 

 

 

 
Operating Expenses
 

 

 

 
Research and development
630,636

895,176

1,212,248

1,595,321
General and administrative
1,621,095

1,718,774

3,153,110

3,211,735
Amortization and depreciation
53,201

53,202

106,403

107,781
Foreign exchange loss (gain)
(18,136)

47,753

38,858

28,443
Total operating expenses
2,286,796

2,714,905

4,510,619

4,943,280


 

 

 

 
Other Income (Expense)
 

 

 

 
Interest and other income
74,379

30,536

168,144

87,630
Finance expense
-

(351,549)

-

(351,549)
Loss before income taxes
(2,028,223)

(2,575,024)

(3,755,122)

(4,252,892)


 

 

 

 
Tax expense
-

-

-

-
Net loss for the period
(2,028,223)

(2,575,024)

(3,755,122)

(4,252,892)


 

 

 

 
Net loss per share for the period
 

 

 

 
Basic and diluted
(0.51)

(3.64)

(0.95)

(6.43)
 
 

 

 

 
Basic and diluted
3,954,549

706,546

3,954,549

661,052
 Table 3. Consolidated Statements of Cash Flows
Expressed in U.S. Dollars

For the Six Months Ended 
December 31,


2025

2024


$

$
Cash provided by (used in):












Operating Activities





Net loss
(3,755,122)

(4,252,892)
Items not requiring cash:
 

 
Amortization and depreciation
106,403

107,782
Share-based compensation
45,469

52,123
Amortization of right-of-use assets
208,296

166,277
Inventory write-down
70,000

-
Interest income received on short-term investments
(774)

(874)
Unrealized foreign exchange loss
3,250

20,338
Changes in operating assets and liabilities:
 

 
Inventories
(56,725)

140,968
Prepaids and other currents assets
(337,050)

(166,237)
Accounts receivable
282,137)

90,269
Accounts payable and accrued liabilities
(332,414)

(282,778)
Lease obligations
(217,329)

(203,924)
Total cash used in operating activities
(3,983,859)

(4,328,948)


 

 
Investing Activities
 

 
Sale of short-term investments
25,156

24,002
Purchase of short-term investments
(25,156)

(24,002)
Total cash used in investing activities
-

-


 

 
Financing Activities
 

 
Proceeds from the private placement
-

1,426,216
Share issuance costs
(137,178)

(249,456)
Total cash (used in) provided by financing activities
(137,178)

1,176,760
Decrease in cash and cash equivalents during the period
(4,121,037)

(3,152,188)
Cash and cash equivalents beginning of the period
11,075,871

6,571,610
Cash and cash equivalents end of the period
6,954,834

3,419,422


 

 
SUPPLEMENTARY CASH FLOW INFORMATION:
 

 
Cash paid during the period for:
-

-
Income taxes$-
$-
Interest$-
$-


 

 
SUPPLEMENTARY DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:
Recognition of Right-of-use asset and corresponding operating lease$-
$187,223
 About InMed: InMed Pharmaceuticals is a pharmaceutical drug development company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors. InMed's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications. For more information, visit www.inmedpharma.com.Investor Contact:
Colin Clancy
Vice President, Investor Relations
and Corporate Communications
T: +1.604.416.0999
E: ir@inmedpharma.comCautionary Note Regarding Forward-Looking Information: This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities laws. Forward-looking statements are frequently, but not always, identified by words such as "expects", "anticipates", "believes", "intends", "potential", "possible", "would" and similar expressions. Such statements, based as they are on current expectations of management, inherently involve numerous risks, uncertainties and assumptions, known and unknown, many of which are beyond our control. Forward-looking information is based on management's current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Without limiting the foregoing, forward-looking information in this news release includes, but is not limited to, statements about: the Act, the impact of the Act on BayMedica, any potential modifications to the Act and/or the timing thereof and the alternative options available to BayMedica and the Company; the potential efficacy of INM-901, INM-901's ability to treat Alzheimer's, marketability and uses for INM-901; statements regarding InMed's belief that modulating neuroinflammation is the primary focus of INM-901, while also targeting several additional biological pathways associated with disease progression; statements about pharmacokinetic studies in large animal models for INM-901; the advancement of chemistry, manufacturing, and controls (CMC) activities, the planning of GLP-enabling studies, and the preparation of an IND submission the further development; potential efficacy, and marketability of INM-089 for dry age-related macular degeneration; Preparing for a pre-IND meeting with the FDA in the second half of calendar 2026 for INM-089; GLP-enabling studies to support an IND submission; expectations regarding the sufficiency of the Company's strengthened balance sheet to fund operations, advance pharmaceutical development programs, and achieve milestones into the fourth quarter of calendar year 2026; and, other business initiatives, strategies, and prospects of the Company.Additionally, there are known and unknown risk factors which could cause InMed's actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. A complete discussion of the risks and uncertainties facing InMed's stand-alone business is disclosed in InMed's Annual Report on Form 10-K, in Item 1A. of the Quarterly Report for the period ended December 31, 2025 and other filings with the Securities and Exchange Commission on www.sec.gov.All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283590
Original: InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Get ready 😎

Inmed Pharamaceuticals Inc. (NASDAQ: INM): Virtual Investor Conferences



Weekly Chart
https://schrts.co/YWSAkHMq

Daily Chart
https://schrts.co/CUTGINrv

inm..................................................https://stockcharts.com/sc3/ui/?s=INM&p=W&b=5&g=0&id=p86431144783

$1.55 + 23%Bounce off 52 week low $1.23 animal results 

$1.91 Maybe it will have a animal move to $2s

It's been a while for INM pump

$1.79 Be happy with $2s this round

Waiting to be promoted by YouTube channels. Low market cap with higher achievements. This could no time hit 100$ IMO

INM huge news this morning https://finance.yahoo.com/news/inmeds-inm-901-significantly-reduces-110000270.html

$INM: Awaaayyyyyyy she goes.... now $4.50

Big premarket booster from just 2.50

NICEEeeeeeeeeeeeeeeeeeeeee


GO $INM

In at $6 LFG

Alzheimer's reduced inflammation...INM $3.35 +10% with that 500k float can pop it ant day maybe today..lol

Should see another big RS same time next year! They are experts at it.

INM: Results of their, "Pre-Clinical MODEL"???? (What an evasive PR!!! Was their study in MICE?? In mere Petri Dishes?? Or, merely in their COMPUTERS????)
https://www.stocktitan.net/news/INM/in-med-s-inm-901-demonstrates-statistically-significant-reduction-in-fn1p6qditmuf.html (PURE, WITCH-DOCTOREY BULLSHIT!!!)

Flip out $8.50s and be happy 

Great news $7.74 + 55%

INM.........................https://stockcharts.com/h-sc/ui?s=INM&p=W&b=5&g=0&id=p86431144783

Reverse split completed keep an eye $5.33 +'25%

Back to .25

Cool..................

Z

Getting some love PM

INM........................https://stockcharts.com/h-sc/ui?s=INM&p=W&b=5&g=0&id=p86431144783

They just don't run like they used to.......sigh...

Z

Thanks for the tip on this one Bill, took a little longer than I thought it would, better late than never. Chee, Chee, Chee

News!!

Vancouver, British Columbia--(Newsfile Corp. - August 21, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it has been issued three U.S. patents: one for its formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one for biosynthesis manufacturing processes and one for an ocular drug delivery formulation.

The method of use patent, entitled "Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders" relates to INM-755 drug candidate which has completed a Phase 2 clinical trial in the treatment of symptoms related to epidermolysis bullosa. The patent has now been granted in the U.S., Australia, Japan and Israel and is pending in several other jurisdictions. The biosynthesis patent for the manufacturing of proprietary analogs for our drug development programs has been granted in U.S. Additionally, an ocular drug delivery formulation and use patent has been granted/allowed in the U.S., Europe, Australia, Japan, and India and is also pending in other jurisdictions.

As of August 20, 2024, InMed has a total of 13 patent families covering new chemical entities, formulations, manufacturing processes and methods of use. The Company continues to pursue new chemical entity patents on the drug candidates for both its INM-901 program in Alzheimer's disease and INM-089 in dry Age-related Macular Degeneration.

Summary of Granted Patents (to date):

Subject Matter
Scope
Status and jurisdiction
Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders
Method of Use
Granted: US, Australia, Japan, Israel

Pending: Several jurisdictions
Metabolic engineering of E. coli for the biosynthesis of cannabinoid products
Manufacturing Process
Granted: U.S. (will be issued on 9/3/24)

Pending: Several jurisdictions
Ocular drug delivery formulation
Formulation, Method of Use
Granted/Allowed: Australia, Japan, India, Europe, U.S.
Recombinant production systems for prenylated polyketides of the cannabinoid family
Manufacturing Process
Granted: U.S., Mexico

Pending: Several jurisdictions


InMed's President and CEO, Eric A. Adams, said "We are pleased to announce these U.S. patent issuances which help increase the commercial value of our programs and ensure the long-term protection of our drug research and development efforts. We are committed to continuing to build our patent portfolio to protect our novel drug candidates, methods of manufacturing these drugs, how they are formulated and how they are used to support the development of new treatments for diseases with high unmet medical needs."

Back to .31 already...wow.

$INM +191% - #DDAmanda Video Analysis - #1 Stock Scanner/Screener



Z

Hope pre market will be a repeat of this morning !

INM: Well then, NICE friend there, Fella!!! (Other than such NICE FRIENDS, below is what anybody's got in today's 'Wall Street' CASINO!!)


And the above BEAR figure --- at the end of the cartoon --- is very APROPOS to today's Markets!!!

Thank You...I was alerted by a friend to watch it when it was trading in the .2s so when it fell from mid .2s into teens I bought...but as you know it went ahead and fell down into the low teens...the only regret is that I didn't average/add down from my .1928 entry....still pretty happy with the return I did get.

INM: CONGRATS to yah, Home Boy!!! (LOVE-it!! Wish I had listened to Ms. Reena's alert!!! Did YOU simply get it on your OWN scanner???)

In at .1928...out at .7221
Anyone could have EASILY tripled their play in the Pre-M here

Nope! lol

INM: A purely PRE-MARKET play, if there ever was one!! WOW!! (I almost grabbed this puppy behind the "Reena969" alert early today, when this was up by 'only' 145%, but I didn't!! DAMN-IT!! Anyone could have EASILY tripled their play in the Pre-M here --- assuming a REASONABLE toss at it --- and otherwise LISTENING carefully when Ms. Reena posts something like, "INM is running".)

Welp….

maybe $+ soon

I’m in , going up from here !